A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and 3.8 million deaths worldwide. Throughout the past year, multiple vaccines have already been developed and used, while some others are in the process of being developed. However, the emergence of new mutant strains of SARS-CoV-2 that have demonstrated immune-evading characteristics and an increase in infective capabilities leads to potential ineffectiveness of the vaccines against these variants. The purpose of this review article is to highlight the current understanding of the immunological mechanisms of the virus and vaccines, as well as to investigate some key variants and mutations of the virus driving the current pandemic and their impacts on current management guidelines. We also discussed new technologies being developed for the prevention, treatment, and detection of SARS-CoV-2. In this paper, we thoroughly reviewed and provided crucial information on SARS-CoV-2 virology, vaccines and drugs being used and developed for its prevention and treatment, as well as important variant strains. Our review paper will be beneficial to health care professionals and researchers so they can have a better understanding of the basic sciences, prevention, and clinical treatment of COVID-19 during the pandemic. This paper consists of the most updated information that has been available as of June 21, 2021.

Keywords

severe acute respiratory syndrome coronavirus 2 / coronavirus disease 2019 / vaccines / variant strains / antiviral therapy

References

[1] RothanHA, ByrareddySN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 2020, 109: 102433

[2] HatmalMM, AlshaerW, Al-HatamlehMAI, et al.. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells, 2020, 9(12): 2638

[3] MastersPS. Coronavirus genomic RNA packaging. Virology, 2019, 537: 198-207

[4] KaurN, SinghR, DarZ, et al.. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. Infect Genet Evol, 2021, 89: 104490

[5] ZhouP, YangXL, WangXG, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798): 270-273

[6] BaiC, WarshelA. Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV. J Phys Chem B, 2020, 124(28): 5907-5912

[7] HuangY, YangC, XuXF, et al.. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin, 2020, 41(9): 1141-1149

[8] OzonoS, ZhangY, OdeH, et al.. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun, 2021, 12(1): 848

[9] RahmanN, BasharatZ, YousufM, et al.. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Molecules, 2020, 25(10): 2271

[10] HoffmannM, Kleine-WeberH, SchroederS, et al.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 181(2): 271-80

[11] ZhouZ, ZhaoN, ShuY, et al.. Effect of Gastrointestinal Symptoms in Patients With COVID-19. Gastroenterology, 2020, 158(8): 2294-2297

[12] PerisettiA, GoyalH, GajendranM, et al.. Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19. Front Med, 2020, 7: 588711

[13] O’HearnM, LiuJ, CudheaF, et al.. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc, 2021, 10(5): e019259

[14] Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality— preliminary results. medRxiv, 2020,02.24.20027268

[15] GheblawiM, WangK, ViveirosA, et al.. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res, 2020, 126(10): 1456-1474

[16] CoperchiniF, ChiovatoL, CroceL, et al.. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev, 2020, 53: 25

[17] FaqihiF, AlharthyA, MemishZA, et al.. Comment on Hu et al: The cytokine storm and COVID-19. J Med Virol, 2021, 93(2): 631-633

[18] BiswasS, ThakurV, KaurP, et al.. Blood clots in COVID-19 patients: Simplifying the curious mystery. Med Hypotheses, 2021, 146: 110371

[19] HuangQ, WuX, ZhengX, et al.. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res, 2020, 159: 105051

[20] TayMZ, PohCM, RéniaL, et al.. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol, 2020, 20(6): 363-374

[21] ZhengHY, ZhangM, YangCX, et al.. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol, 2020, 17(5): 541-543

[22] ChowdhuryMA, HossainN, KashemMA, et al.. Immune response in COVID-19: A review. J Infect Public Health, 2020, 13(11): 1619-1629

[23] LeeWS, WheatleyAK, KentSJ, et al.. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol, 2020, 5(10): 1185-1191

[24] TiradoSM, YoonKJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol, 2003, 16(1): 69-86

[25] RickeDO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol, 2021, 12: 640093

[26] HuangQ, ZengJ, YanJ. COVID-19 mRNA vaccines. J Genet Genomics, 2021, 48(2): 107-114

[27] LivingstonEH, MalaniPN, CreechCB. The Johnson & Johnson Vaccine for COVID-19. JAMA, 2021, 325(15): 1575

[28] Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA, 2021, e218565. doi: https://doi.org/10.1001/jama.2021.8565. Epub ahead of prrnt. PMID: 34037666; PMCID: PMC8156175.

[29] XiaS, ZhangY, WangY, et al.. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 2021, 21(1): 39-51

[30] WuZ, HuY, XuM, et al.. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(6): 803-812

[31] XuS, YangK, LiR, et al.. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci, 2020, 21(18): 6582

[32] CagigiA, LoréK. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines, 2021, 9(1): 61

[33] Linares-FernándezS, LacroixC, ExpositoJY, et al.. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med, 2020, 26(3): 311-323

[34] SchoenmakerL, WitzigmannD, KulkarniJA, et al.. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm, 2021, 601: 120586

[35] DyerO. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. BMJ, 2021, 373: n883

[36] XiaS, DuanK, ZhangY, et al.. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 2020, 324(10): 951-960

[37] ZhangY, ZengG, PanH, et al.. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192

[38] GolobJL, LugogoN, LauringAS, et al.. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6(9): 149187

[39] ZhuFC, LiYH, GuanXH, et al.. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020, 395(10240): 1845-1854

[40] MallapatyS. China’s COVID vaccines are going globalbut questions remain. Nature, 2021, 593(7858): 178-179

[41] LogunovDY, DolzhikovaIV, ShcheblyakovDV, et al.. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681

[42] LogunovDY, DolzhikovaIV, ZubkovaOV, et al.. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, 2020, 396(10255): 887-897

[43] ChungYH, BeissV, FieringSN, et al.. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano, 2020, 14(10): 12 522-12 537

[44] WadmanM. The long shot. Science, 2020, 370(6517): 649-653

[45] MedhiR, SrinoiP, NgoN, et al.. Nanoparticle-Based Strategies to Combat COVID-19. ACS Appl Nano Mater, 2020, 3(9): 8557-8580

[46] AshrafMU, KimY, KumarS, et al.. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9(2): 171

[47] Moore AC, Dora EG, Peinovich N, et al. Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection. bioRxiv, 2020.09.04.283853; doi: https://doi.org/10.1101/2020.09.04.283853

[48] CubukJ, AlstonJJ, InciccoJJ, et al.. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat Commun, 2021, 12(1): 1936

[49] NooraeiS, BahrulolumH, HoseiniZS, et al.. Viruslike particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology, 2021, 19(1): 59

[50] MahmoodN, NasirSB, HefferonK. Plant-Based Drugs and Vaccines for COVID-19. Vaccines, 2020, 9(1): 15

[51] Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Medicine, 2021. doi: https://doi.org/10.1038/s41591-021-01377-8. Epub ahead of print. PMID: 34002089.

[52] WuK, WernerAP, KochM, et al.. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med, 2021, 384(15): 1468-1470

[53] van OosterhoutC, HallN, LyH, et al.. COVID-19 evolution during the pandemic— Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence, 2021, 12(1): 507-508

[54] Abdool KarimSS, de OliveiraT. New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications. N Engl J Med, 2021, 384(19): 1866-1868

[55] ZouJ, XieX, Fontes-GarfiasCR, et al.. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccrne-elicited neutralization. NPJ Vaccines, 2021, 6(1): 44

[56] KorberB, FischerWM, GnanakaranS, et al.. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020, 182(4): 812-827

[57] PlanteJA, LiuY, LiuJ, et al.. Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 2021, 592(7852): 116-121

[58] PlanasD, BruelT, GrzelakL, et al.. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med, 2021, 27(5): 917-924

[59] ShenX, TangH, McDanalC, et al.. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe, 2021, 29(4): 529-539

[60] SupasaP, ZhouD, DejnirattisaiW, et al.. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184(8): 2201-2211

[61] Zhou H, Dcosta BM, Samanovic MI, et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv, 2021.03.24.436620; doi: https://doi.org/10.1101/2021.03.24.436620

[62] Annavajhala MK, Mohri H, Zucker JE, et al. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv, 2021.02.23.21252259. doi: https://doi.org/10.1101/2021.02.23.21252259

[63] GreaneyAJ, LoesAN, CrawfordKHD, et al.. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe, 2021, 29(3): 463-476

[64] KuzminaA, KhalailaY, VoloshinO, et al.. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or postvaccination sera. Cell Host Microbe, 2021, 29(4): 522-528

[65] EdaraVV, NorwoodC, FloydK, et al.. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe, 2021, 29(4): 516-521

[66] ShindeV, BhikhaS, HoosainZ, et al.. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med, 2021, 384(20): 1899-1909

[67] MadhiSA, BaillieV, CutlandCL, et al.. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med, 2021, 384(20): 1885-1898

[68] TooveyOTR, HarveyKN, BirdPW, et al.. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect, 2021, 82(5): e23-e4

[69] Sapkal G, Yadav PD, Ella R, et al. Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine. bioRxiv, 2021,04.30.441559. doi: https://doi.org/10.1101/2021.04.30.441559

[70] Garcia-Beltran WF, Lam EC, St Denis K, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv, 2021.02.14.21251704. doi: https://doi.org/10.1101/2021.02.14.21251704

[71] Hirotsu Y, Omata M. Discovery of SARS-CoV-2 strain of P.1 lineage harboring K417T/E484K/N501Y by whole genome sequencing in the city, Japan. medRxiv, 2021.02.24.21251892. doi: https://doi.org/10.1101/2021.02.24.21251892

[72] DejnirattisaiW, ZhouD, SupasaP, et al.. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184(11): 2939-2954

[73] Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv, 2021.04.22.440932. doi: https://doi.org/10.1101/2021.04.22.440932

[74] Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv, 2021.04.02.438288. doi: https://doi.org/10.1101/2021.04.02.438288

[75] Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv, 2021.03.07.21252647. doi: https://doi.org/10.1101/2021.03.07.21252647

[76] NazirSUR, NazirT, SultanaM, et al.. The Potentially Recommended Pharmacotherapy for COVID-19. Altern Ther Health Med, 2021, 27(S1): 24-28

[77] DrożdżalS, RosikJ, LechowiczK, et al.. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat, 2020, 53: 100719

[78] KokicG, HillenHS, TegunovD, et al.. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun, 2021, 12(1): 279

[79] BeigelJH, TomashekKM, DoddLE, et al.. Remdesivir for the Treatment of Covid-19—Final Report. N Engl J Med, 2020, 383(19): 1813-1826

[80] WhiteKM, RosalesR, YildizS, et al.. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 2021, 371(6532): 926-931

[81] MartinezMA. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. Antimicrob Agents Chemother, 2021, 65(4): e00200-21

[82] CoxRM, WolfJD, PlemperRK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol, 2021, 6(1): 11-18

[83] GottliebRL, NirulaA, ChenP, et al.. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA, 2021, 325(7): 632-644

[84] DebP, MollaMMA, Saif-Ur-RahmanKM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosafety Health, 2021, 3(2): 87-91

[85] LiR, MaX, DengJ, et al.. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cell Mol Immunol, 2021, 18(4): 1058-1060

[86] AcharyaKP, GhimireTR, SubramanyaSH. Access to and equitable distribution of COVID-19 vaccine in low-income countries. NPJ Vaccines, 2021, 6(1): 54

[87] QuastI, TarlintonD. B cell memory: understanding COVID-19. Immunity, 2021, 54(2): 205-210

[88] RahimiH, SalehiabarM, BarsbayM, et al.. CRISPR Systems for COVID-19 Diagnosis. ACS Sens, 2021, 6(4): 1430-1445